Related Experiment Video

Updated: Mar 24, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

[A case of gastric endocrine cell carcinoma which was significantly reduced in size by radiotherapy]

Kiyoshi Azakami1, Kouji Nishida, Ken Tanikawa

  • 1Gastroenterology, Sankoukai Miyazaki Hospital.

Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics
|March 4, 2016
PubMed

Insights

Palliative radiotherapy can effectively manage symptoms in elderly patients with unresectable gastric neuroendocrine carcinoma (NEC). This case study confirms radiotherapy

Area of Science:

  • Oncology
  • Gastroenterology
  • Radiotherapy

Background:

  • Gastric neuroendocrine tumors (NETs) are classified by the WHO into NET G1, NET G2, and neuroendocrine carcinoma (NEC).
  • Neuroendocrine carcinomas (NECs) present a poor prognosis.
  • Advanced gastric cancer requires tailored treatment strategies, especially in elderly patients with poor performance status.

Observation:

  • An 84-year-old female presented with advanced gastric cancer (type 3) causing stenosis.
  • The patient's condition precluded surgery or intensive chemotherapy.
  • Palliative radiotherapy was administered to manage symptoms and tumor burden.

Findings:

  • Radiotherapy led to significant tumor size reduction and alleviated obstructive symptoms.
  • Autopsy confirmed gastric endocrine cell carcinoma and pathologically validated radiotherapy's effectiveness.
  • The patient survived for 9 months post-radiotherapy.

Implications:

  • Palliative radiotherapy offers a viable option for symptom relief in elderly patients with unresectable advanced gastric NEC.
  • This approach may improve quality of life for patients ineligible for aggressive treatments.
  • Further research into palliative radiotherapy for advanced gastric NEC is warranted.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Stereotactic Radiosurgery for Gynecologic Cancer10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.8K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
735
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
786